Amphastar Pharmaceuticals (AMPH) Expected to Announce Quarterly Earnings on Wednesday

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Amphastar Pharmaceuticals to post earnings of $1.01 per share and revenue of $188.78 million for the quarter.

Amphastar Pharmaceuticals Stock Performance

AMPH stock traded down $0.02 during mid-day trading on Friday, reaching $31.28. 523,506 shares of the stock traded hands, compared to its average volume of 535,354. The firm has a market capitalization of $1.50 billion, a PE ratio of 10.43, a P/E/G ratio of 2.19 and a beta of 0.81. The business has a 50-day moving average of $35.84 and a two-hundred day moving average of $43.00. Amphastar Pharmaceuticals has a 52 week low of $30.34 and a 52 week high of $56.38. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Insider Activity at Amphastar Pharmaceuticals

In related news, EVP Rong Zhou sold 7,000 shares of the firm's stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the completion of the transaction, the executive vice president now directly owns 118,469 shares of the company's stock, valued at $5,262,392.98. This trade represents a 5.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard K. Prins sold 10,000 shares of the business's stock in a transaction on Monday, December 9th. The shares were sold at an average price of $43.77, for a total transaction of $437,700.00. Following the completion of the sale, the director now directly owns 30,471 shares in the company, valued at $1,333,715.67. This trade represents a 24.71 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 27.10% of the company's stock.

Analyst Ratings Changes

A number of research firms have issued reports on AMPH. Wells Fargo & Company initiated coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 target price on the stock. StockNews.com cut Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, November 1st. Finally, Piper Sandler lowered shares of Amphastar Pharmaceuticals from an "overweight" rating to a "neutral" rating and dropped their target price for the stock from $66.00 to $36.00 in a research report on Tuesday, February 4th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $50.33.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.